SCHEDULE: Coastlands Capital Exits Neuphoria Therapeutics Stake

Coastlands Capital LP and affiliated entities have filed an exit statement for their beneficial ownership of Neuphoria Therapeutics Inc. common stock, no longer holding over 5% of the class.

Summary

• Coastlands Capital LP, along with its associated entities (Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry), has filed an amendment to their Schedule 13G.
• This filing serves as an exit statement, indicating that these reporting persons no longer beneficially own more than 5% of the common stock of Neuphoria Therapeutics Inc.
• As of May 14, 2026, the reporting persons collectively held 228,594 shares, representing 4.23% of the outstanding common stock.
• The calculation of beneficial ownership was based on 5,404,551 shares of common stock outstanding as reported by Neuphoria Therapeutics Inc. in its Form 10-Q filed on May 15, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the lack of explanation for the exit, which could lead to market speculation.

Positives

• The reporting persons have successfully exited their position above the 5% threshold, indicating a potential strategic divestment or portfolio adjustment.
• The filing is clean and clearly states the exit, providing transparency to the market.

Negatives

• The filing does not provide specific reasons for the divestment, leaving the market to speculate on the underlying causes.

Risks

• The exit of a significant shareholder could be interpreted by the market as a lack of confidence in the company's future prospects, potentially impacting share price.
• The lack of detailed explanation for the exit leaves room for negative speculation regarding potential undisclosed issues with Neuphoria Therapeutics Inc.

Future Outlook

The filing is an exit statement and does not contain forward-looking statements or guidance from the company regarding its future performance.

Management Comments

• Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein.
• The filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically used by passive investors. An exit filing like this, especially without further explanation, can sometimes signal a shift in investor sentiment or a strategic decision to reallocate capital away from the company.

Stakeholder Impact

• Shareholders may interpret the exit of a significant holder as a negative signal, potentially affecting share price.
• The market will observe if other institutional investors follow suit or if the company can attract new significant holders.

Next Steps

• The reporting persons will no longer be required to file Schedule 13G amendments for Neuphoria Therapeutics Inc. unless their beneficial ownership increases above the 5% threshold again.

Key Dates

Keywords

Schedule 13G, Exit Filing, Beneficial Ownership, Neuphoria Therapeutics, Coastlands Capital, Shareholder, SEC Filing, Common Stock